141 related articles for article (PubMed ID: 37060431)
1. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Chee CE; Ooi M; Lee SC; Sundar R; Heong V; Yong WP; Ng CH; Wong A; Lim JSJ; Tan DSP; Soo R; Tan JTC; Yang S; Thura M; Al-Aidaroos AQ; Chng WJ; Zeng Q; Goh BC
Target Oncol; 2023 May; 18(3):391-402. PubMed ID: 37060431
[TBL] [Abstract][Full Text] [Related]
2. Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP; Thura M; Gupta A; Tan SH; Kuan KKY; Ang KH; Merchant K; Chang KTE; Yon HY; Chen Y; Cheng MHW; Mahadev A; Ng MCH; Seng MS; Iyer P; Chia PL; Soh SY; Zeng Q
Mol Ther Oncolytics; 2023 Sep; 30():153-166. PubMed ID: 37674627
[TBL] [Abstract][Full Text] [Related]
3. PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
Thura M; Al-Aidaroos AQO; Yong WP; Kono K; Gupta A; Lin YB; Mimura K; Thiery JP; Goh BC; Tan P; Soo R; Hong CW; Wang L; Lin SJ; Chen E; Rha SY; Chung HC; Li J; Nandi S; Yuen HF; Zhang SD; Guan YK; So J; Zeng Q
JCI Insight; 2016 Jun; 1(9):e87607. PubMed ID: 27699276
[TBL] [Abstract][Full Text] [Related]
4. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; Zhou J; Wang LZ; Yuen JSP; Ho HSS; Yi SM; Chiong E; Choo SP; Ngeow J; Ng MCH; Chua C; Yeo ESA; Tan IBH; Sng JXE; Tan NYZ; Thiery JP; Goh BC; Zeng Q
Nat Commun; 2019 Jun; 10(1):2484. PubMed ID: 31171773
[TBL] [Abstract][Full Text] [Related]
5. PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.
Thura M; Ye Z; Al-Aidaroos AQ; Xiong Q; Ong JY; Gupta A; Li J; Guo K; Ang KH; Zeng Q
Commun Biol; 2021 Jul; 4(1):923. PubMed ID: 34326464
[TBL] [Abstract][Full Text] [Related]
6. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
7. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
8. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
10. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saif MW; Knost JA; Chiorean EG; Kambhampati SR; Yu D; Pytowski B; Qin A; Kauh JS; O'Neil BH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):815-24. PubMed ID: 27566701
[TBL] [Abstract][Full Text] [Related]
12. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
[TBL] [Abstract][Full Text] [Related]
13. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.
Borazanci E; Schram AM; Garralda E; Brana I; Vieito Villar M; Spreafico A; Oliva M; Lakhani NJ; Hoffman K; Hallett RM; Maetzel D; Hua F; Hilbert J; Giblin P; Anido J; Kelly A; Vickers PJ; Wasserman R; Seoane J; Siu LL; Hyman DM; Hoff DV; Tabernero J
ESMO Open; 2022 Aug; 7(4):100530. PubMed ID: 35921760
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Abaza YM; Kadia TM; Jabbour EJ; Konopleva MY; Borthakur G; Ferrajoli A; Estrov Z; Wierda WG; Alfonso A; Chong TH; Chuah C; Koh LP; Goh BC; Chang JE; Durkes DE; Foudray MC; Kantarjian HM; Dong XQ; Garcia-Manero G
Cancer; 2017 Dec; 123(24):4851-4859. PubMed ID: 28841236
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
[TBL] [Abstract][Full Text] [Related]
16. Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Stein EM; DeAngelo DJ; Chromik J; Chatterjee M; Bauer S; Lin CC; Suarez C; de Vos F; Steeghs N; Cassier PA; Tai D; Kiladjian JJ; Yamamoto N; Mous R; Esteve J; Minami H; Ferretti S; Guerreiro N; Meille C; Radhakrishnan R; Pereira B; Mariconti L; Halilovic E; Fabre C; Carpio C
Clin Cancer Res; 2022 Mar; 28(5):870-881. PubMed ID: 34862243
[TBL] [Abstract][Full Text] [Related]
17. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis EJ; Martin-Liberal J; Kristeleit R; Cho DC; Blagden SP; Berthold D; Cardin DB; Vieito M; Miller RE; Hari Dass P; Orcurto A; Spencer K; Janik JE; Clark J; Condamine T; Pulini J; Chen X; Mehnert JM
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36316061
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
19. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
